GlobeNewsWire
07 Jan 2026, 21:05 UTC · 36w ago
Verdict
Headline takes no side. We score TERN +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Terns Pharmaceuticals has approximately $1.0 billion in cash and marketable securities, providing a financial runway into 2031.
So whatSignificant cash reserves eliminate immediate dilution risk and provide high stability for a clinical-stage biotech company.
More positive than 91% of claims this week
The company plans to initiate a pivotal trial for 2L+ (second-line and beyond) treatment of CML in late 2026 or early 2027.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 76% of claims this week
TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025.
More positive than 64% of claims this week
Terns expects pivotal dose selection and an End-of-Phase 2 (EOP2) regulatory interaction in mid-2026.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company reports strong cash runway into 2031, FDA Fast Track designation for TERN-701, and positive momentum in its CARDINAL trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
+32.4%
Price agrees with the score
$52.95 vs $40.00 close before publication (Jan 7) · not market-adjusted
TERN chart →
